Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'.
Gilbert
Peter B
PB
Department of Biostatistics, University of Washington, Seattle, WA 98109, USA. pgilbert@scharp.org
Qin
Li
L
Self
Steven G
SG
D015415:Biomarkers; D001699:Biometry / Q000379:methods*; D003627:Data Interpretation, Statistical; D006801:Humans; D015233:Models, Statistical; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D014612:Vaccines / Q000494:pharmacology
D015415:Biomarkers; D014612:Vaccines